EN DE
Watch BioNexus Gene Lab Corp Common stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BioNexus Gene Lab Corp (BGLC) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of BioNexus Gene Lab Corp stock $1.64, price $0.86, upside +91.5%, quality 31 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials US · Based in Malaysia

BG BioNexus Gene Lab Corp logo Thin data Nov 6, 2026

BioNexus Gene Lab Corp

BGLC · US
Cheap, value-trap risk

The stock costs 48% less than our calculation considers fair.

Fair value $1.64 · Strongly undervalued (48%)
Even on cautious assumptions the value is 26% above the price ($1.08).
Quality 31/100
Weak Growth (revenue 5y −8.2 %/yr in USD)
Loss-making · -82.4% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 8/100 · thin data
Thin data
⟳ Cyclical
Watch BioNexus Gene Lab Corp Common stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$59.50 $0.8565 Fair Value $1.64 Sep 2020 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $0.8565 – $59.50 · fair‑value band $1.08 – $2.05 · the $0.8565 price screens below the $1.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow BioNexus Gene Lab Corp Common stock in your weekly email

Every Wednesday you see whether BioNexus Gene Lab Corp Common stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia.

Show moreShow less

The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.

It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process.

The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing.

It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Stock analysis

BioNexus Gene Lab Corp (BGLC) currently trades at $0.8565, while our model-based Fair Value estimate is $1.64, implying the stock looks roughly 48% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $1.08 (bear) to $2.05 (bull), the price of $0.8565 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Basic Materials sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

BioNexus Gene Lab Corp Common stock reported revenue of $7.4M in FY2025 versus $13.4M in FY2021, a compound −13.7%/yr. Reported net income was −$3.0M in FY2025.

Key figures

Market cap $2.8M Micro · P/S ratio 0.88 · EPS (TTM) $−1.26 · Dividend yield 0.8% · Net margin −82.4% · Return on equity −33.7% · Return on assets (EBIT) −12.9% · Operating margin −399%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 84% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −44% fair-value upside, at 91%, BGLC screens cheaper than that median.

Fair Value models

Bear $1.08 Fair Value $1.64 Bull $2.05
Price $0.8565 · Upside +91.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $1.08 $1.64 $2.05 52
All 1 models by family
Asset-Based
NCAV (Graham) $1.08 $1.64 $2.05 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 16
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 82
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 5, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−21.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+69.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.2% (2020) → −42.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BGLC, get fair value alerts →

Compare BioNexus Gene Lab Corp Common stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 727 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside +91.5% · Top 25%
Profitability
Return on assets −32.3% · Bottom 25%
Net margin (12 months) −82.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −96.6% · Bottom 25%
Dividend yield (12 months) 0.8% · Below median

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/B 0.32× · Cheapest 25%
P/S (12 months) 0.88× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 67
PAST (return on equity)0 · sector 27
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)16 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Nan Ya Plastics Corporation 1303 249.00 TWD 398.40 TWD +60% vs BGLC
Wanhua Chemical Group 600309 ¥73.58 ¥68.03 −8% vs BGLC
Linde plc LIN $521.23 $446.62 −14% vs BGLC
PPG Industries, Inc PPG $123.27 $77.68 −37% vs BGLC
DSM-Firmenich AG DSFIR CHF 103.20 CHF 57.82 −44% vs BGLC
Sika AG SIKA CHF 188.75 CHF 98.89 −48% vs BGLC
The Sherwin-Williams Company SHW $349.01 $146.37 −58% vs BGLC
Givaudan SA GIVN CHF 4,105 CHF 1,554 −62% vs BGLC
EMS-CHEMIE HOLDING AG EMSN CHF 859.50 CHF 284.63 −67% vs BGLC
Ecolab Inc ECL $305.83 $96.56 −68% vs BGLC

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BioNexus Gene Lab Corp Common stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BioNexus Gene Lab Corp Common stock Fair Value". https://www.fairvalue-calculator.com/stock/BGLC

Frequently asked questions

Is BioNexus Gene Lab Corp (BGLC) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $1.64 versus a price of $0.8565, about +91% upside (undervalued).
What is the fair value of BGLC?
Our model-based fair value for BioNexus Gene Lab Corp Common stock is $1.64 (as of Nov 6, 2026), built from audited fundamentals. The current price: $0.8565.
What is the quality score of BGLC?
BioNexus Gene Lab Corp Common stock has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioNexus Gene Lab Corp (BGLC)?
Our model-based price target is the fair value of $1.64 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $1.08, optimistic scenario $2.05. It is a calculation from audited fundamentals, not an analyst target.
What is the BioNexus Gene Lab Corp Common stock stock forecast for 2026?
Our models put fair value at $1.64, about +91% upside versus a price of $0.8565 (undervalued). Cautious scenario $1.08, optimistic scenario $2.05. The calculation is refreshed regularly with new filings.
What is the revenue of BioNexus Gene Lab Corp (BGLC)?
BioNexus Gene Lab Corp Common stock reported trailing-twelve-month revenue of about $3.1M (latest available figure, as of Nov 6, 2026).
Does BioNexus Gene Lab Corp Common stock pay a dividend?
BioNexus Gene Lab Corp Common stock currently shows a dividend yield of 0.80% relative to its recent price (as of Nov 6, 2026).
What is the intrinsic value of BioNexus Gene Lab Corp (BGLC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioNexus Gene Lab Corp Common stock it is $1.64 per share (as of Nov 6, 2026), against a price of $0.8565. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is BioNexus Gene Lab Corp Common stock stock overvalued or undervalued in 2026?
As of Nov 6, 2026, BGLC trades below its calculated fair value: price $0.8565, fair value $1.64, a gap of about +91% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BGLC?
No. The price is what the market pays today ($0.8565); the fair value is what the company's own numbers justify ($1.64). For BioNexus Gene Lab Corp Common stock the two are $0.7835 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioNexus Gene Lab Corp Common stock worth?
The market values BioNexus Gene Lab Corp Common stock at about $2.8M (market capitalisation, as of Nov 6, 2026). Per share that is $0.8565; our models calculate a fair value of $1.64 per share.
What do the bullish and bearish scenarios say about BGLC?
Our models span a range for BioNexus Gene Lab Corp Common stock: cautious scenario $1.08, base $1.64, optimistic $2.05 per share (as of Nov 6, 2026, price $0.8565). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BioNexus Gene Lab Corp (BGLC)?
Balance-sheet figures for BioNexus Gene Lab Corp Common stock (as of Nov 6, 2026): return on equity −33.7%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is BGLC from its 52-week high?
BioNexus Gene Lab Corp Common stock trades at $0.8565, about 84% below its 52-week high of $5.39 and at the low of $0.8565 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $1.64 is for.
Which stocks are comparable to BioNexus Gene Lab Corp Common stock?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioNexus Gene Lab Corp Common stock stock attractive at the current price?
The data as of Nov 6, 2026: price $0.8565, calculated fair value $1.64 (+91%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BGLC calculated?
We run BioNexus Gene Lab Corp Common stock through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. BioNexus Gene Lab Corp Common stock currently trades 48% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioNexus Gene Lab Corp (BGLC)?
The closing price on Nov 5, 2026 was $0.8565. Our model-based fair value is $1.64, about +91% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioNexus Gene Lab Corp Common stock right now?
The large discount to fair value meets weak quality (31/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($1.08). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.08 to $2.05) leaves room in how you read the outcome.

Key figures of BioNexus Gene Lab Corp Common stock

How large is the market capitalisation of BioNexus Gene Lab Corp (BGLC)?
The market capitalisation of BioNexus Gene Lab Corp Common stock is $2.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioNexus Gene Lab Corp (BGLC)?
The price-to-sales ratio of BioNexus Gene Lab Corp Common stock is 0.88 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioNexus Gene Lab Corp (BGLC)?
Earnings per share at BioNexus Gene Lab Corp Common stock are $−1.26. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BioNexus Gene Lab Corp (BGLC)?
The dividend yield of BioNexus Gene Lab Corp Common stock is 0.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BioNexus Gene Lab Corp (BGLC)?
The net margin of BioNexus Gene Lab Corp Common stock is −82.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioNexus Gene Lab Corp (BGLC)?
The return on equity (ROE) of BioNexus Gene Lab Corp Common stock is −33.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioNexus Gene Lab Corp (BGLC)?
On an EBIT basis the return on assets of BioNexus Gene Lab Corp Common stock is −12.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioNexus Gene Lab Corp (BGLC)?
The operating margin of BioNexus Gene Lab Corp Common stock is −399% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioNexus Gene Lab Corp (BGLC)?
Revenue at BioNexus Gene Lab Corp Common stock is growing −96.6% versus a year earlier (3y avg −12.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioNexus Gene Lab Corp (BGLC)?
Earnings per share at BioNexus Gene Lab Corp Common stock are growing −95.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BioNexus Gene Lab Corp (BGLC) generate?
The free cash flow of BioNexus Gene Lab Corp Common stock is −$1.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BioNexus Gene Lab Corp (BGLC) hold?
BioNexus Gene Lab Corp Common stock holds more cash than debt, $2.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BioNexus Gene Lab Corp Common stock in the live analysis

One click puts BioNexus Gene Lab Corp Common stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.